Clinical trial
A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia®) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.
NCT01140321 is registered in ClinicalTrials.gov with Ente Ospedaliero Ospedali Galliera as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia®) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.
- Lead sponsor
- Ente Ospedaliero Ospedali Galliera
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- May 31, 2010
- Enrollment
- 120 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
osteoporosis, thalassemia intermedia, thalassemia major